In Vivo Antidiabetic Potential and Safety of Aqueous Extract of Triticum Aestivum (Wheatgrass)
Loading...
Date
2017
Authors
Njoroge, G.K.
Njagi, E.N.M.
Gikonyo, N.K.
Piero, M.N.
Journal Title
Journal ISSN
Volume Title
Publisher
Trans Stellar
Abstract
Primary goal in management of diabetes mellitus is to realize normoglycaemia. Like many other plants,
Triticum aestivum has been used widely in complementary and alternative medicine but minimal data is available on its
effectiveness and toxicity effects. This study was done to evaluate in vivo glycemic and toxicity effects of Triticum
aestivum. 10% alloxan monohydrate was administered intraperitoneally in Swiss White Albino rats to induce diabetes in
determination of efficacy. Rats with blood glucose levels above 200 mg/L were orally administered with aqueous extracts
of Triticum aestivum plant at 50, 90.9, 165.1 and 300mg/kg body weight. Glibenclamide was used as the positive control.
Toxicity studies were done post oral administration of either 300, 448.14, 669.4 or 1000mg per kilogram body weight of
plant extracts for 28 days. The weights of the rats organs, haematological and biochemical parameters were used for
toxicity studies. p ≤ 0.05 was considered statistically significant. The results obtained in this study indicated that the
young plant of Triticum aestivum has therapeutic benefits in treatment of diabetes mellitus. No chronic toxicity effects
were established. Use of Triticum aestivum as mono therapy for diabetes should be recommended on carrying out
clinical studies in humans.
Description
Research Article
Keywords
Normoglycemia, Triticum aestivum, Glibenclamide, In vivo, Alloxan, Efficacy & Toxicity
Citation
International Journal of Medicine and Pharmaceutical Science (IJMPS) Vol. 7, Issue 1, Feb 2017, 77-84